3 ms·
> I am assuming people in the study were younger people who needed the money and not older folks who are at a higher risk. That may be true in the earlier phas
by tzs 6y ago
> I am assuming people in the study were younger people who needed the money and not older folks who are at a higher risk.
That may be true in the earlier phases, when you are just trying to show that the vaccine isn't too harmful and works in at least some cases.
It's not true for the large phase 3 trials. For those you try for a study group that matches the demographics of the people who will be getting the vaccine in the wild.
For the J&J phase 3 trial, 34% of the participants were over 60. 41% had comorbidities associated with an increased risk for progression to severe COVID. Race was 74% white, 13% black, 6% Asian, and 1% Native American. Ethnicity was 15% Hispanic.
Pfizer was 45% age 56-85, Moderna was 16% over 65. Race for both was about 80% white, 10% black, 4-5% Asian, 1% Native. Ethnicity was 26% Hispanic for Pfizer, 20% for Moderna. I don't know what percent had comorbidities.